# Complying to Regulation (EC) 1907/2006

# Material Safety Data Sheet Synthadon 10 mg/ml solution for injection



# SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY UNDERTAKING

1.1 Product identification

**Product name(s):** Synthadon 10 mg/ml solution for injection

Product code(s): XVD 107 (10 ml vial)

1.2 Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses: Veterinary medicinal product

**Uses advised against:** Not for human use. Refer to the product information leaflet

Reasons why uses advised against: Refer to the product information leaflet

1.3 Details of the supplier of the safety data sheet

Company name: Animalcare Limited
Address: 10 Great Northway
York Business Park

Nether Poppleton York YO26 6RB

United Kingdom

1.4 Emergency telephone number

**Daytime:** +44 (0) 1904 487687

# SECTION 2: HAZARDS IDENTIFICATION

# 2.1 Classification of the substance or mixture

Classification according to Regulation (EC) 1272/2008

This is a veterinary medicinal product authorised under the provisions of Directive 2001/82/EC. Classification of this substance/mixture is not required according to

point 11 of the preamble in Regulation EC 1272/2008.

2.2 Label elements

**Labelling according to Regulation** 

(EC) 1272/2008

This is a veterinary medicinal product authorised under the provisions of Directive 2001/82/EC. Label elements for this substance/mixture is not required according

to point 11 of the preamble in Regulation EC 1272/2008.

Hazard pictograms: Not applicable
Signal word: Not applicable
Hazard statements: Not applicable
Precautionary statements: Not applicable

**Supplemental information:** May cause drowsiness or dizziness. Suspected of causing genetic defects. Suspected

of damaging fertility or the unborn child. Possibly fatal if swallowed

2.3 Other hazards

Hazard(s) not otherwise classified (HNOC)

Medical conditions aggravated: Liver impairment. Kidney impairment. Hypothyroidism. Seizure disorders. Asthma. Respiratory disorders. Heart arrhythmia. Alcoholism. History of drug abuse or dependence. Gallbladder disorders. Inflammatory bowel disease. Urinary disorders. Low blood pressure.

Gastrointestinal obstruction. Adrenal gland problems. Sickle cell disease. Addison's

disease. Concurrent use of monoamine oxidase inhibitors (MAOIs).

# SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.2 Mixtures

Substance name in the mixture	CAS No	Quantity
Methadone Hydrochloride	[1095-90-5]	1%
Methyl-4-hydroxybenzoate	[99-76-3]	0.1%
Propyl-4-hydroxybenzoate	[94-13-3]	0.02%
Sodium chloride	[7647-14-5]	Proprietary
Water for injection	[7789-20-0]	Proprietary

# **SECTION 4: FIRST AID MEASURES**

# 4.1 Description of first aid measures

**Eyes:** Rinse with water. Get medical attention if irritation develops and persists

Skin: Rinse with water/shower. Get medical attention if irritation develops and persists

Ingestion: Call a physician immediately. Do not drive. Rinse mouth thoroughly. Do not induce

vomiting without advice. If vomiting occurs, keep head low so that stomach content doesn't get into the lungs. Do not use mouth-to-mouth method if victim ingested the substance. Induce artificial respiration with the aid of a pocket mask equipped

with a one-way valve or other proper respiratory medical device

**Injection:** Call a physician immediately. Do not drive

# 4.2 Most important symptoms and effects, both acute and delayed

See section 11 for more information on health effects and symptoms

### 4.3 Indication of any immediate medical attention and special treatment needed

See patient package insert in shipping carton for complete information.

No specific measures identified. Seek medical advice if required

# **SECTION 5: FIRE- FIGHTING MEASURES**

5.1 Extinguishing media

Suitable extinguishing media: Use extinguishing measures that are appropriate to local circumstances and the

surrounding environment

Unsuitable extinguishing media: None known

5.2 Special hazards arising from the substance or mixture

Specific hazards during

firefighting:

Not flammable or combustible

Hazardous combustion products: Decomposition products may include the following materials: Carbon oxides (CO<sub>x</sub>),

nitrogen oxides (NO<sub>x</sub>)

**5.3** Advice for fire-fighters

Special protective equipment for

firefighters:

Use personal protective equipment

Further information: Fire residues and contaminated fire extinguishing water must be disposed of in

accordance with local regulations

#### **SECTION 6: ACCIDENTAL RELEASE MEASURES**

# Personal precautions, protective equipment and emergency procedures

Advice for non-emergency Refer to protective measures listed in sections 7 and 8

personnel:

Advice for emergency responders: If specialised clothing is required to deal with the spillage, take note of any

information is section 8 on suitable and unsuitable materials

# 6.2 Environmental precautions

Make sure spills can be contained, e.g. in sump pallets or kerbed areas. Do not allow to enter into surface water of drains. Do not allow to enter into soil/subsoil.

# Methods and material for containment and cleaning up

**Small spills:** Wear recommended personal protective equipment (see section 8- Exposure

controls/personal Protection). Use absorbent towels or brooms to clean up spill.

Wipe surface area clean with soap and water

Large spills: Dike spilled material or otherwise contain material to ensure runoff does not reach

a waterway

# Reference to other sections

See Section 1 for emergency contact information

See section 8 for personal protection

See Section 13 for additional waste treatment information

#### **SECTION 7: HANDLING AND STORAGE**

# **Precautions for safe handling**

Advice on safe handling: When handling pharmaceutical products, avoid all contact and inhalation of dust,

fumes, mist, and/or vapors associated with the product

Hygiene measures: None identified

# 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas

Keep out of reach of children. Keep in the original packaging. Keep container tightly

and containers:

closed

Storage temperature:

Store at ambient temperature

Further information on storage

Keep in a dry, cool and well-ventilated place

conditions:

# 7.3 Specific end use(s)

Recommendations: Read the Product Information Leaflet before use

#### **SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION**

#### 8.1 **Control parameters**

The following constituents are the only constituents of the product which have a PEL, TLV, TWA or other recommended exposure limit. At this time, none of the constituents have known exposure limits

# **Exposure controls**

Good general ventilation should be sufficient to control worker exposure to **Engineering measures:** 

airborne contaminants

Individual protection measures:

No specific measures identified Hygiene measures:

**Eye/face protection:** Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet

the standards in accordance with EN166, ANSI Z87.1 or international equivalent)

**Skin/body protection:** Impervious disposable protective clothing is recommended if skin contact with drug

product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international

equivalent)

Hand protection: Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin

contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001

or international equivalent)

**Respiratory protection:** Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL)

is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143,

ASTM F2704-10 or international equivalent)

Environmental exposure controls: Consider the provision of containment around storage vessels

# **SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**

# 9.1 Information on basic physical and chemical properties

Appearance Liquid

Colour: Clear colourless

Odour: None

**Odour threshold:** No data available No data available :Ha **Density:** No data available Melting point: No data available **Boiling point:** No data available Flash point: No data available **Evaporation rate:** No data available Flammability: No data available Water solubility: No data available **Partition coefficient:** No data available **Auto-ignition temperature:** No data available Thermal decomposition: No data available Viscosity: No data available No data available Vapour pressure: Vapour density: No data available **Explosive properties:** No data available

Oxidizing properties: The substance or mixture is not classified as oxidizing

# 9.2 Other information

No data available.

# **SECTION 10: STABILITY AND REACTIVITY**

# 10.1 Reactivity

No dangerous reaction known under normal conditions of normal use

# 10.2 Chemical stability

Stable under normal conditions

# 10.3 Possibility of hazardous reactions

No dangerous reaction known under normal conditions of normal use

#### 10.4 Conditions to avoid

Avoid contact with incompatible materials

# 10.5 Incompatible materials

None Known

# 10.6 Hazardous decomposition products

Decomposition products may include the following materials: Carbon oxides nitrogen oxides

# **SECTION 11: TOXICOLOGICAL INFORMATION**

# 11.1 Information on toxicological effects

**Acute toxicity:** Methadone HCl LD<sub>50</sub> 124 mg/kg (Mouse)

Methadone HCI LD<sub>50</sub> 86 mg/kg (Rat)

Category 3, narcotic effects

Chronic toxicity: No data available
Skin irritation/sensitization: No data available

**Reproductive toxicity:** Category 2. Suspected of damaging fertility or the unborn child. Maternal use of

opioids during pregnancy may cause physical dependence in the fetus leading to respiratory difficulties and withdrawal symptoms (dehydration, irritability, tremors, excessive crying, diarrhea) in the newborn. Therapeutic use of this

material may reduce sperm motility in men

Carcinogenicity: Not classified or listed by IARC, NTP, OSHA, EU and ACGIH. No drug related

carcinogenic/tumorigenic effects based on animal data

**Mutagenicity:** Category 2. Suspected of causing genetic defects

# **SECTION 12: ECOLOGICAL INFORMATION**

#### 12.1 Toxicity

No data available

# 12.2 Persistence and degradability

No data available

# 12.3 Bioaccumulative potential

No data available

# 12.4 Mobility in soil

No data available

# 12.5 Results of PBT and vPvB assessment

No data available

## 12.6 Other adverse effects

No data available

# SECTION 13: DISPOSAL CONSIDERATIONS

# 13.1 Waste treatment methods

Dispose of in accordance with the European Directives on waste and hazardous waste. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Dispose of as unused product. Empty containers should be taken to an approved waste handling site for recycling or disposal. Do not re-use empty containers

# SECTION 14: TRANSPORT INFORMATION

DOT Hazard Class: Transport hazard class(es) 6.1

Subsidiary class(es) Not available.

Packing group II

IATA: Transport hazard class(es) 6.1

Subsidiary class(es): -. Packing group II

Shipping Label: N.A.

# **SECTION 15: REGULATORY INFORMATION**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

This product has been authorised under the provisions of Directive 2001/82/EC

# 15.2 Chemical safety assessment

For this product, a chemical safety assessment was not carried out

# **SECTION 16: OTHER INFORMATION**

For animal treatment only

We believe the statements, technical information and recommendations contained herein are reliable, but they are given without warranty or guarantee of any kind, express or implied, and we assume no responsibility for any loss, damage or expense, direct or consequential, arising out of their use

End of document